opnurasib,jdq443,tislelizumab
novartis,beigene
['kontrast-01', 'jdq443', 'sclc', 'lcsm,(-blcsm)', 'nsclc']
 presented an update on kontrast-01 on the safety and efficacy of jdq443 in kras g12c-mutated #nsclc. results look promising, good safety data, more studies already on the way. #lcsm #asco23 
LUNGevity, the nation’s leading lung cancer organization, is transforming what it means to be diagnosed and live with lung cancer.